3 citations
,
January 2023 in “Clinical cancer investigation journal” This theoretical study suggests that certain cannabinoid derivatives could potentially be effective as androgen receptor and 5α-reductase enzyme inhibitors, indicating they may be promising candidates for prostate cancer treatment based on their higher affinity to target proteins compared to standard drugs.
January 2024 in “Clinical dermatology open access journal” This paper reviews existing research on the cosmetic benefits of hemp-derived cannabinoids for skin and hair, highlighting their unique mechanisms of action, while discussing formulation, legal, and regulatory challenges associated with using these compounds in cosmetic products.
50 citations
,
May 2019 in “Drugs” This review discusses the potential therapeutic effects of targeting the endocannabinoid system for chemotherapy-induced peripheral neuropathy and reports no new clinical results, highlighting the need for ongoing research.
14 citations
,
February 2021 in “Experimental Dermatology” This study found that activating CB1 receptor signaling in human hair follicles increased stem cell proliferation while reducing differentiated cell survival, suggesting CB1's role as a survival stimulus for epithelial stem cells.
88 citations
,
February 2008 in “Journal of Medicinal Chemistry” Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.